Got 90 seconds? Then listen to Imagion Biosystems president and CEO Robert Proulx tell us more about the company and its recent investor update.

Imagion Biosystems (ASX: IBX) is a med-tech company developing a new non radioactive and safe diagnostic imaging technology.

Combining biotechnology and nanotechnology the company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. In July, Imagion announced that its flagship MagSense technology was granted designation as a Breakthrough Device by the FDA.

We gave Imagion Biosystems’ President and CEO Robert Proulx 90 seconds to tell us more about the company’s technology and recent announcements.

Have a good idea for our next 90 Seconds With segment? Email us at tv@stockhead.com.au.